Remdesivir, the first possible scientifically proven treatment for battling COVID-19, will become available for U.S. hospitals in the coming week, says the CEO of the biotech company producing the drug.
On CBS’s “Face the Nation” Sunday morning, Gilead Sciences CEO Daniel O’Day said the company had donated 1.5 million vials to the U.S. government, enough to treat 150,000 to 200,000 patients.
Federal health officials will outlay the drug “based on things like ICU beds, where the course of the epidemic is in the United States,” O’Day said. “They will begin shipping tens of thousands of treatment courses out early this week.”
Last week, early results from a global study conducted by the U.S. National Institute of Allergy and Infectious Diseases found patients given the experimental drug remdesivir recovered faster and may be less likely to die. Patients who received remdesivir had a 31% faster recovery time than those who received a placebo, the study found.
– Mike Snider(USATODAY)